Neurocrine Biosciences reported $343M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Exelixis USD 268.42M 20.01M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pfizer USD 662M 5M Sep/2026
Prothena USD -18.69M 44.48M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Repligen USD 24.31M 3.18M Sep/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Teva Pharmaceutical Industries USD 1.19B 954M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026